VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® in India from the Directorate General of Health Services Office of Drug Controller General (India) – the Indian equivalent of the FDA. India is an important country for this nine country clinical trial because about 15 of the 48 clinical centers for this global trial will be located in India and because India has the greatest number of head and neck cancer cases in the world. It is expected that patient enrollment in India will be about 4-6 times faster than would be possible in US clinical centers. The global Phase III trial for Multikine was started in the United States in late December 2010. CEL-SCI expects to commence the trial in other countries around the world within the next 30-60 days. Multikine is the Company’s flagship immunotherapy developed as a first-line standard of care in the treatment of head and neck cancer.
